CD97 (F1B5E) Rabbit Monoclonal Antibody #42684
- WB
- IHC
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 80, 50 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:400 - 1:1600 |
Storage
实验步骤
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
CD97 exhibits the broadest expression pattern among EGF-TM7 family members, and is found on various cell types, including hematopoietic stem and progenitor cells, and other immune cells. It has been reported to play a role in leukocyte development, activation, and migration (3-5). It is also present on smooth muscle cells (e.g., vascular, skeletal, heart muscle cells), where it is thought to contribute to cell adhesion and muscle development (6). Through its EGF-like domains, CD97 can interact with various extracellular ligands, including CD55/DAF, chondroitin sulfate B, and selected integrins. These interactions mediate cell-cell and cell-matrix adhesion, and influence cell migration via activation of RhoA, Akt, and ERK signaling pathways (2,7,8). Upregulated CD97 is observed in a variety of human cancers, including gastric, colorectal, pancreatic, thyroid, and brain cancers, and its expression often correlates with advanced tumor stage, increased invasiveness, and poor patient prognosis. It has been shown that CD97 can enhance cancer cell migration, invasion, and metastasis, and promote angiogenesis by stimulating endothelial cell motility and invasion. Its soluble form can also act as a chemoattractant. In tumor cells, CD97 can activate pro-tumorigenic signaling via β-catenin, Akt, and RhoA pathways, contributing to cell proliferation and survival. CD97 interaction with tumor microenvironment components, including chondroitin sulfate and other adhesion molecules, can facilitate tumor growth and spread (2,6-9).
- Lin, H.H. et al. (2000) Genomics 67, 188-200.
- Safaee, M. et al. (2013) Int J Oncol 43, 1343-50.
- Stacey, M. et al. (2003) Blood 102, 2916-24.
- Kop, E.N. et al. (2009) Immunol Lett 123, 160-8.
- Capasso, M. et al. (2006) J Immunol 177, 1070-7.
- Aust, G. et al. (2006) Cell Tissue Res 324, 139-47.
- Somasundaram, A. et al. (2014) Neurosurg Focus 37, E14.
- Wang, T. et al. (2005) Blood 105, 2836-44.
- Ishikawa, N. et al. (2004) Clin Cancer Res 10, 8363-70.
Alternate Names
ADGRE5; Adhesion G protein-coupled receptor E5; Adhesion G protein-coupled receptor E5 subunit alpha; Adhesion G protein-coupled receptor E5 subunit beta; AGRE5; CD97; CD97 antigen; CD97 antigen subunit alpha; CD97 antigen subunit beta; CD97 molecule; Leukocyte antigen CD97; seven transmembrane helix receptor; seven-span transmembrane protein; seven-transmembrane, heterodimeric receptor associated with inflammation; TM7LN1
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专